37
Participants
Start Date
January 31, 2017
Primary Completion Date
August 11, 2017
Study Completion Date
August 11, 2017
GLPG2222 150 mg q.d.
GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
GLPG2222 300 mg q.d.
GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
Placebo
Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
The Prince Charles Hospital, Chermside
The Alfred, Melbourne
Sir Charles Gairdner Hospital, Nedlands
Westmead Hospital, Westmead
UZ Brussel, Brussels
UZ Gent, Ghent
UZ Leuven, Leuven
Fakultni nemocnice v Motole, Prague
Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden
Universitätsklinikum Erlangen, Erlangen
University Children´s Hospital, Tübingen
Cork University Hospital, Cork
Beaumont Hospital, Dublin
St Vincents University Hospital, Dublin
Birmingham Heartlands, Birmingham
Royal Devon and Exeter, Exeter
St James's University, Leeds
Liverpool Heart and Chest Hospital, Liverpool
Royal Brompton Hospital, London
University Hospital of South Manchester, Manchester
Royal Victoria Infirmary, Newcastle
Southampton General Hospital, Southampton
Lead Sponsor
Galapagos NV
INDUSTRY